Abstract
Autocrine and paracrine signaling leading to stimulation of tumor cell growth is a common theme in human cancers. In addition to polypeptide growth factors such as EGF family members which signal through receptor tyrosine kinases, accumulating evidence supports the autocrine and paracrine involvement of specific neuropeptides with defined physiologic actions as neurotransmitters and gut hormones in lung, gastric, colorectal, pancreatic and prostatic cancers. These neuropeptides, including gastrin-releasing peptide, neuromedin B, neurotensin, gastrin, cholecystokinin and arginine vasopressin bind seven transmembrane-spanning receptors that couple to heterotrimeric G proteins. Studies with human small cell lung cancer (SCLC) cells support a requirement for balanced signaling through Gq and G12/13 proteins leading to intracellular Ca2+ mobilization, PKC activation and regulation of the ERK and JNK MAP kinase pathways. While specific neuropeptide antagonists offer promise for interrupting the single neuropeptide autocrine systems operating in pancreatic and prostatic cancers, SCLC is exemplified by multiple, redundant neuropeptide autocrine systems such that tumor growth cannot be inhibited with a single specific antagonist. However, a novel class of neuropeptide derivatives based on the substance P sequence have been defined that exhibit broad specificity for neuropeptide receptors and induce apoptosis in SCLC by functioning as biased agonists that stimulate discordant signal transduction. Thus, interruption of autocrine and paracrine neuropeptide signaling with specific antagonists or broad-spectrum biased agonists offer promising new therapeutic approaches to the treatment of human cancers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aprikian AG, Han K, Chevalier S, Bazinet M, Viallet J . 1996 J. Mol. Endocrinol. 16: 297–306
Aprikian AG, Han K, Guy L, Landry F, Begin LR, Chevalier S . 1998 Prostate Suppl. 8: 52–61
Baldwin GS . 1995 J. Gastroenterol. Hepatol. 10: 215–232
Baldwin GS, Shulke A . 1998 Gut 42: 581–584
Barr AJ, Brass LF, Manning DR . 1997 J. Biol. Chem. 272: 2223–2229
Bartholdi MF, Wu JM, Pu H, Troncoso P, Eden PA, Feldman RI . 1998 Int. J. Cancer 79: 82–90
Battey J, Wada E . 1991 Trends Neurosci. 14: 524–528
Beekman A, Helfrich B, Bunn Jr. PA, Heasley LE . 1998 Cancer Res. 58: 910–913
Blackmore M, Hirst BH . 1992 Br. J. Cancer 66: 32–38
Buhl AM, Johnson NL, Dhanasekaran N, Johnson GL . 1995 J. Biol. Chem. 270: 24631–24634
Bunn Jr. PA, Chan D, Dienhart DG, Tolley R, Tagawa M, Jewett PB . 1992 Cancer Res. 52: 24–31
Burbach JP, Meijer OC . 1992 Eur. J. Pharmacol. 227: 1–18
Cardona C, Rabbitts PH, Spindel ER, Ghatei MA, Bleehen NM, Bloom SR, Reeve JG . 1991 Cancer Res. 51: 5205–5211
Chatzistamou I, Schally AV, Sun B, Armatis P, Szepeshazi K . 2000 Br. J. Cancer 83: 906–913
Chave HS, Gough AC, Palmer K, Preston SR, Primrose JN . 2000 Br. J. Cancer. 82: 124–130
Collins LR, Minden A, Karin M, Brown JH . 1996 J. Biol. Chem. 271: 17349–17353
Corjay MH, Dobrzanski DJ, Way JM, Vialley J, Shapira H, Worland P, Sausville EA, Battey JF . 1991 J. Biol. Chem. 266: 18771–18779
Coulson JM, Fiskerstrand CE, Woll PJ, Quinn JP . 1999a Cancer Res. 59: 5123–5127
Coulson JM, Stanley J, Woll PJ . 1999b Br. J. Cancer 80: 1935–1944
Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD . 1985 Nature 316: 823–826
Davis TP, Crowell S, McInturff B, Louis R, Gillespie T . 1991 Peptides 12: 17–23
Dhanasekaran N, Heasley LE, Johnson GL . 1995 Endocrine Rev. 16: 259–270
Dockray GJ . 1999 J. Physiol. 518: 315–324
Everard MJ, Macaulay VM, Millar JL, Smith IE . 1993 Eur. J. Cancer 29A: 1450–1453
Fathi Z, Corjay MH, Shapira H, Wada E, Benya R, Jensen R, Viallet J, Sausville EA, Battey JF . 1993 J. Biol. Chem. 268: 5979–5984
Fruhawald MC, O'Dorisio MS, Cottingham SL, Qualman SJ, O'Dorisio TM . 1998 Ann. New York Acad. Sci. 865: 420–426
Geijer T, Folkesson R, Rehfeld JF, Monstein H-J . 1990 FEBS Lett. 270: 30–32
Goetze JP, Nielsen FC, Burcharth F, Rehfeld JF . 2000 Cancer 88: 2487–2494
Gohla A, Offermanns S, Wilkie TM, Schultz G . 1999 J. Biol. Chem. 274: 17901–17907
Gorbulev V, Akhundova A, Buchner H, Fahrenholz F . 1992 Eur. J. Biochem. 208: 405–410
Gross AJ, Steinberg SM, Reilly JG, Bliss Jr. DP, Brennan J, Le PT, Simmons A, Phelps R, Mulshine JL, Ihde DC, Johnson BE . 1993 Cancer Res. 53: 67–74
Hamilton BP, Upton GV, Amatruda Jr. TT . 1972 Clin. Endocrinol. Metab. 35: 764–767
Heasley LE, Zamarripa J, Storey B, Helfrich B, Mitchell FM, Bunn Jr. PA, Johnson GL . 1996a J. Biol. Chem. 271: 349–354
Heasley LE, Storey B, Fanger GR, Zamarripa J, Maue RA . 1996b Mol. Cell. Biol. 16: 648–656
Higashita R, Li L, Van Putten V, Yamamura Y, Zarinetchi F, Heasley L, Nemenoff RA . 1997 J. Biol. Chem. 272: 25845–25850
Hong M, Moody TW . 1991 Peptides 12: 1315–1319
Ivell R, Schmale H, Richter D . 1983 Neuroendocrinol. 37: 235–240
Jarpe MB, Knall C, Mitchell FM, Buhl AM, Duzic E, Johnson GL . 1998 J. Biol. Chem. 273: 3097–3104
Jian X, Sainz E, Clark WA, Jensen RT, Battey JF, Northup JK . 1999 J. Biol. Chem. 274: 11573–11581
Kozasa T, Jiang X, Hart MJ, Sternweis PM, Singer WD, Gilman AG, Bollag G, Sternweis PC . 1998 Science 280: 2109–2111
Langdon S, Sethi T, Ritchie A, Muir M, Smyth J, Rozengurt E . 1992 Cancer Res. 52: 4554–4557
Lawlor ER, Lim JF, Tao W, Poremba C, Chow CJ, Kalousek IV, Kovar H, MacDonald TJ, Sorensen PH . 1998 Cancer Res. 58: 2469–2476
Lobaugh LA, Eisfelder B, Gibson K, Johnson GL, Putney Jr. JW . 1996 Mol. Pharmacol. 50: 493–500
MacKinnon AC, Armstrong RA, Waters CM, Cummings J, Smyth JF, Haslett C, Sethi T . 1999 Br. J. Cancer 80: 1026–1034
Mahmoud S, Staley J, Taylor J, Bogden A, Moreau J-PL, Coy D, Avis I, Cuttitta F, Mulshine JL, Moody TW . 1991 Cancer Res. 51: 1798–1802
Mao J, Xie W, Yuan H, Simon MI, Mano H, Wu D . 1998 EMBO J. 17: 5638–5646
Markowitz S, Krystal G, Lebacq-Perheyden AM, Way J, Sausville EA, Battey J . 1988 J. Clin. Invest. 82: 808–815
Markwalder R, Reubi JC . 1999 Cancer Res. 59: 1152–1159
Miller YE . 1989 Am. Rev. Respira. Dis. 140: 283–284
Mitchell FM, Heasley LE, Qian N-X, Zamarripa J, Johnson GL . 1995 J. Biol. Chem. 270: 8623–8628
Moody TW, Pert CB, Gazdar AF, Carney DN, Minna JD . 1981 Science 214: 1246–1248
Moody TW, Carney DN, Korman LY, Gazdar AF, Minna JD . 1985 Life Sci. 36: 1727–1732
Moody TW, Staley J, Zia F, Coy DH, Jensen RT . 1992 J. Pharmacol. Exp. Ther. 263: 311–317
Nagalla SR, Spindel ER . 1994 Cancer Res. 54: 4461–4467
Nagao M, Kaziro Y, Itoh H . 1999 Oncogene 18: 4425–4434
Nelson JB, Carducci MA . 2000 Cancer Invest. 18: 87–96
Nemenoff RA . 1998 Front. Biosci. 3: D194–D207
North WG . 1991 J. Clin. Endocrinol. Metab. 73: 1316–1320
North WG, Fay MJ, Longo KA, Du J . 1998 Cancer Res. 58: 1866–1871
Nyeki O, Rill A, Schon I, Orosz A, Schrett J, Bartha L, Nagy J . 1998 J. Pept. Sci. 4: 486–495
Ohki-Hamazaki H . 2000 Prog. Neurobiol. 62: 297–312
Ohki-Hamazaki H, Watase K, Yamamoto K, Ogura H, Yamano M, Yamada K, Maeno H, Imaki J, Kikuyama S, Wada E, Wada K . 1997 Nature 390: 165–169
Paolucci L, Rozengurt E . 1999 Cancer Res. 59: 572–577
Picon A, Leblond-Francillard M, Raffin-Sanson ML, Lenne F, Bertagna X, de Keyzer Y . 1995 J. Mol. Endocrinol. 15: 187–194
Quick MW, Lester HA, Davidson N, Simon MI, Aragay AM . 1996 J. Biol. Chem. 271: 32021–32027
Reeve JG, Bleehen NM . 1994 Bioc. Biop. Res. Comm. 199: 1313–1319
Reubi JC, Schaer JC, Waser B . 1997 Cancer Res. 57: 1377–1386
Rosati R, Adil MR, Ali MA, Eliason J, Orosz A, Sebestyen F, Kalemkerian GP . 1998 Peptides 19: 1519–1523
Sausville E, Carney D, Battey J . 1985 J. Biol. Chem. 260: 10236–10241
Schonwasser DC, Marais RM, Marshall CJ, Parker PJ . 1998 Mol. Cell. Biol. 18: 790–798
Seckl MJ, Higgins T, Widmer F, Rozengurt E . 1997 Cancer Res. 57: 51–54
Seethalakshmi L, Mitra SP, Dobner PR, Menon M, Carraway RE . 1997 Prostate 31: 183–192
Sehgal I, Powers S, Huntley B, Powis G, Pittelkow M, Maihle NJ . 1994 Proc. Natl. Acad. Sci. USA 91: 4673–4677
Sethi T, Rozengurt E . 1991 Cancer Res. 51: 3621–3623
Sethi T, Rozengurt E . 1992 Cancer Res. 52: 6031–6035
Sethi T, Langdon S, Smyth J, Rozengurt E . 1992 Cancer Res. 52: 2737s–2742s
Sethi T, Herget T, Wu SV, Walsh JH, Rozengurt E . 1993 Cancer Res. 53: 5208–5213
Seufferlein T, Rozengurt E . 1996 Cancer Res. 56: 5758–5764
Smith JP, Liu G, Soundararajan V, McLaughlin PJ, Zagon IS . 1994 Am. J. Physiol. 266: R277–R283
Smith JP, Shih A, Wu Y, McLaughlin PJ, Zagon IS . 1996 Am. J. Physiol. 270: R1078–R1084
Staley J, Fiskum G, Moody TW . 1989 Biochem. Biophys. Res. Comm. 163: 605–610
Staley J, Jensen RT, Moody TW . 1990 Peptides 11: 1033–1036
Strassheim D, Shafer SH, Phelps SH, Williams CL . 2000 Cancer Res. 60: 2730–2736
Sun B, Halmos G, Schally AV, Wang X, Martinez M . 2000a Prostate 42: 295–303
Sun B, Schally AV, Halmos G . 2000b Regul. Pept. 90: 77–84
Sundler F, Ekblad E, Hakanson R . 1991 Acta Oncol. 30: 419–427
Thibonnier M, Berti-Mattera LN, Dulin N, Conarty DM, Mattera R . 1998 Prog. Brain Res. 119: 147–161
Toi-Scott M, Jones CLA, Kane MA . 1996 Lung Cancer 15: 341–354
Vara Prasad MVVS, Dermott JM, Heasley LE, Johnson GL, Dhanasekaran N . 1995 J. Biol. Chem. 270: 18655–18659
Verbeeck MAE, Elands JPM, de Leij LFMH, Buys CHCM, Carney DN, Bepler G, Roebroeck AJM, Van De Ven WJM, Burbach JPH . 1992 Pathobiology 60: 136–142
Vincent J-P, Mazella J, Kitabgi P . 1999 Trends Pharmacol. Sci. 20: 302–309
Wadsworth SJ, Gebauer G, van Rossum GD, Dhanasekaran N . 1997 J. Biol. Chem. 272: 28829–28832
Wank SA . 1995 Am. J. Physiol. 269: G628–G646
Wank SA . 1998 Am. J. Physiol. 274: G607–G613
Watanapa P, Williamson RC . 1993 Br. J. Cancer 67: 877–884
Weinberg DS, Ruggeri B, Barber MT, Biswas S, Miknyocki S, Waldman SA . 1997 J. Clin. Invest. 100: 597–603
Wittau N, Grosse R, Kalkbrenner F, Gohla A, Schultz G, Gudermann T . 2000 Oncogene 19: 4199–4209
Woll PJ, Rozengurt E . 1988 Proc. Natl. Acad. Sci. USA 85: 1859–1863
Woll PJ, Rozengurt E . 1989 Bioc. Biop. Res. Comm. 164: 66–73
Woll PJ, Rozengurt E . 1990 Cancer Res. 50: 3968–3973
Zugaza JL, Waldron RT, Sinnett-Smith J, Rozengurt E . 1997 J. Biol. Chem. 272: 23952–23960
Acknowledgements
I appreciate many helpful discussions regarding this manuscript with Raphael Nemenoff (University of Colorado Health Sciences Center) and support from NIH grants DK19928 and CA58157.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Heasley, L. Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 20, 1563–1569 (2001). https://doi.org/10.1038/sj.onc.1204183
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204183
Keywords
This article is cited by
-
Small-cell lung cancer
Nature Reviews Disease Primers (2021)
-
Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy
Oncogene (2020)
-
Identification of Human Secretome and Membrane Proteome-Based Cancer Biomarkers Utilizing Bioinformatics
The Journal of Membrane Biology (2020)
-
Collagen gel droplet-embedded culture drug sensitivity test for adjuvant chemotherapy after complete resection of non-small-cell lung cancer
Surgery Today (2018)
-
Cytoprotective effect of neuropeptides on cancer stem cells: vasoactive intestinal peptide-induced antiapoptotic signaling
Cell Death & Disease (2017)